Vyome Holdings Inc
vyometx.comWhat Do They Do?
Sells topical antifungal products for people with dandruff and skin fungal diseases, and develops drug candidates for patients with immune-inflammatory and rare diseases.
10-K for FY2025, filed Mar 18, 2026
How Do They Make Money?
Sun Pharma pays licensing and milestone fees for the Luliconazole program, including amounts tied to studies, launch, and sales. For the earlier antifungal products, Vyome receives a net service fee on sales made by Sun Pharma.
10-K for FY2025, filed Mar 18, 2026
-
10-K for FY2025, filed Mar 18, 2026
FY2025 revenue by product or service ↗
$319.7K
-
10-K for FY2025, filed Mar 18, 2026
$319.7K ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Licensing and milestone fees – Luliconazole
Licensed
10-K for FY2025, filed Mar 18, 2026 |
37% |
Licensing and milestone fees – Luliconazole, FY2025
$116.9K Sources
|
Licensed |
|
Sale of products
|
55% |
Sale of products, FY2025
$174.6K Sources
|
|
|
Royalty income related to above product sales
Licensed
|
8.8% |
Royalty income related to above product sales, FY2025
$28.2K Sources
|
Licensed |
Who Are Their Customers?
Sun Pharma markets Vyome’s topical antifungal products in India under licensing and marketing arrangements.
10-K for FY2025, filed Mar 18, 2026
Do Revenues Turn Into Profits?
No. It lost $10.3M in FY2025.
10-K for FY2025, filed Mar 18, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$685.6KView ↗
- ▲ +122% (Loss)
- vs −$308.8K in Q2 FY2025
-
Aug 28, 2026
Jerry Leonard appointed CFO; Robert Dickey resigned as interim CFO
Leonard’s appointment took effect September 1, 2026, after Dickey’s resignation became effective August 31, 2026.
Sources
8-K, filed Aug 28, 2026
On August 27, 2026, the board of directors (the “Board”) of Vyome Holdings, Inc. (the “Company”) appointed Jerry Leonard as the Company’s…View ↗
-
Aug 25, 2026
Licensed two selective JAK inhibitor assets from Impetis
The assets are intended to address autoimmune and inflammatory conditions.
Sources
8-K, filed Aug 25, 2026
Signed agreement with Impetis Biosciences Limited (“Impetis’) to in-license two selective JAK inhibitor assets designed for higher…View ↗
Shrinking. Revenue fell 98% in 4 years, from $13.6M in FY2021 to $319.7K in FY2025, about 61% a year.
From obesity care to specialty pharmaceuticals
The older report centered on bariatric devices, virtual weight-loss coaching, and wellness products for obesity and metabolic health. The latest report centers on drug development for immune-inflammatory and rare diseases, alongside antifungal products.
10-K for FY2022, filed Apr 17, 2023 10-K for FY2025, filed Mar 18, 2026
Who Do They Compete With?
Competes with Tarsier Pharma, Eli Lily, Eyepoint Pharmaceuticals, Bausch Health, Sun Pharma, and Almirall
10-K for FY2025, filed Mar 18, 2026The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong…View ↗
Loading...
